

Access to long-acting pre-exposure prophylaxis (PrEP)

Perspectives from the Medicines Patent Pool

Conflict of Interest Disclosure


- I have no relevant financial relationships with pharmaceutical companies or other conflict of interest to disclose.

Thanks to the entire MPP team!



Acknowledgments


- The work of the Medicines Patent Pool in HIV is made possible by the financial support of Unitaid.
- We thank them, as well as our other current public and philanthropic funders.



Existing PrEP options



Oral PrEP
(TDF/XTC)



365 pills/year



Dapivirine
vaginal ring




12 rings/year

Injectable LA-PrEP options




Cabotegravir



6 injections/year
(7 during first year)



Lenacapavir



2 doubles injections/year
(3 during first year)


Emerging injectable LA-PrEP options

Originator product registration to date



Both are registered in
Malawi

CAB as PrEP
(ViiV Healthcare)



LEN as PrEP
(Gilead Sciences)



Emerging LA-PrEP options

Voluntary licences enabling future access to generics

In the development pipeline

Cabotegravir (2-monthly injectable)

Lenacapavir (6-monthly injectable)

Alimatravir (monthly oral)

Originator **ViiV Healthcare**

Gilead Sciences

MSD

Licence

- Covers at least 133 countries (including countries without patents for CAB)

- Covers 120 countries

- Covers at least 129 countries (including countries without patents for alimatravir)

Licensed generics

3 generic manufacturers

- Aurobindo
- Cipla
- Viatis

6 generic manufacturers


- Dr. Reddy's
- Emcure
- Eva Pharma
- Ferozsons Laboratories
- Hetero
- Viatis

7 generic manufacturers

- Aspen
- Aurobindo
- Cipla
- Emcure
- Quality Chemical Industries
- Universal Corporation
- Viatis

Emerging LA-PrEP options

Countries able to access future generic versions



In summary

*The tools
needed for
effective HIV
prevention exist
& continue to
evolve
HIV prevention also
requires that all PLHIV
have access to optimal
ART*



TLD remains the preferred first-line option

WHO also differentiates its offer

1. TAF-based treatment as alternative to TDF

Daily oral TAF-ED or TAF-LD

Can already be accessed as generic across sub-Saharan Africa!

2. Simplified treatment with two oral ARVs

Daily oral DTG/3TC




Can already be accessed as generic across sub-Saharan Africa!



All of these represent opportunities for

Two-Malawi injectable CAB + RPV

Under development as generic for all of sub-Saharan Africa!



Some recommendations...

PrEP now, PrEP in the future, and the power of U=U

1. Continue expanding access to PrEP to increasing numbers of people and as a menu of options
 2. Continue supporting access to effective HIV treatment, with TLD (and pALD) as central programmatic pillars, and newly-recommended options as needed to help individual adherence and optimize clinical outcomes
 3. Start planning for emerging PrEP and treatment options currently at clinical
1. Oral PrEP, CAB, LEN, DVR
 2. TLD, pALD, TAF-ED, TAF-LD, DTG/3TC
 3. AMI (PrEP), CAB + RPV (treatment)

Thanks for your attention!

Thanks to our funders!



Sébastien Morin
Senior Manager – Policy,
Strategy & Market Access
smorin@mppf.ch



Maureen Luba
Board Member (MPP)
Senior Advisor – Global Policy (AVAC)
maureenluba@gmail.com



And thanks for your collective dedication to HIV care for all

